Communication of April 29, 2026
For nearly eighty years, Stago has been developing solutions grounded in rigorous scientific standards, driven by a constant ambition: to support healthcare professionals and contribute to improved patient care.
As a leading global player in hemostasis, the company has built its identity on a culture of excellence, recognized expertise, and a long-term vision.
Today, Stago is entering a new phase in its history.
The founding family has chosen to transfer Stago to ARCHIMED, a leading investment firm exclusively focused on the healthcare industries holding the expertise and resources to support Stago’s growth and accelerate value creation. La Caisse, a global investment group, is also participating in this transaction as a minority shareholder.
ARCHIMED brings solid experience in supporting high-potential companies. Its sector positioning and long-term approach offer Stago a suitable framework to reach a new milestone.
This change in ownership is part of a structured development strategy that continues Stago’s commitments to its clients. Under ARCHIMED’s and La Caisse’s leadership, the company aims to strengthen its investment capabilities, accelerate its innovation projects, intensify its international expansion, and leverage its scientific expertise in operational and commercial performance.
Building on its solid foundations, Stago is embarking on an ambitious growth phase, where scientific excellence and performance are the two drivers of sustainable development.